However, treating cardiac amyloidosis is a complex task due to the frequent association between systemic congestion and low blood pressure, thrombo-embolic and haemorrhagic risk balance, patient frailty, and generally poor prognosis. The aim of this review is to describe the current state of ...
Cardiac amyloidosis is caused by the extracellular, interstitial deposition of misfolded protein deposits or amyloid fibrils that result in a restrictive cardiomyopathy with associated conduction system and rhythm disturbances. This family of diseases has distinct prognoses and treatment options depending on ...
Cardiac amyloidosis in the United States is most often due to myocardial infiltration by immunoglobulin protein, such as in AL amyloidosis, or by the prote... M Tuzovic,EH Yang,AS Baas,... - 《Current Oncology Reports》 被引量: 9发表: 2017年 Diagnosis and Management of the Cardiac Amyloid...
Recently, ATTRwt has emerged as a potentially relevant cause of a heart failure with preserved ejection fraction (HFpEF). Cardiac amyloidosis is an archetypal example of restrictive cardiomyopathy, with signs and symptoms of global heart failure and diastolic dysfunction. Independent of the aetiology, ...
of ejection fraction treatments related to heart failure, treatment of comorbidities in heart failure patients, diagnosis and treatment of cardiac amyloidosis, the timing of referral to all tertiary hospitals and heart failure specialists, and treatment of acute heart failure patients and severe heart ...
Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis Hiding in Plain Sight: It Looks Like Diabetic Neuropathy but Might Be Hereditary Amyloidosis Clarifying the Natural History of Transthyretin Cardiac Amyloidosis: Insights From the ATTRibute-CM Trial Tools...
Cardiac amyloidosis is an infiltrative disorder caused by extracellular protein deposition. Transthyretin is a proamyloidotic protein that produces one of ... Esther,González-López,ángela,... - 《Revista Espanola De Cardiologia》 被引量: 3发表: 2017年 Pathway for the Diagnosis and Management of ...
Systemic AL amyloidosis (ALA) is a clonal plasma cell (PC) disease characterized by deposition of amyloid fibrils in different organs and tissues. Traditionally, the prognosis of ALA is poor and is primarily defined by cardiac involvement. The modern prognostic models are based on cardiac markers ...
There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR) stabilizers or gene silencers. While many patients may be on both classes of medications, there is no data available on the safety and efficacy of combination ther...
"The heart is the most important abnormality in amyloidosis because if the heart is affected, that is the complete driver of how the patient will do and what their prognosis is," says Dr. Grogan. "That's why cardiac amyloidosis is so important to recognize and treat as early as possible....